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PEMBANGUNAN PERPUSTAKAAN ANTIBODI IMUN BAGI 
TUBERKULOSIS: PENJANAAN ANTIBODI MONOKLONAL UNTUK 
ANTIGEN D-KRYSTALIN 
 
ABSTRAK 
Antibodi adalah amat penting untuk aplikasi terapeutik dan diagnostik untuk 
penyakit berjangkit. Perpustakaan imunisasi adalah perpustakaan yang berguna 
untuk penyakit berjangkit kerana ia akan membolehkan pengkayaan selektif antibodi 
terhadap antigen. Generasi perpustakaan antibodi adalah perlu untuk menghasilkan 
monoclonal antibodi. Perpustakaan antibodi ScFv imunisasi dihasilkan daripada 
enam orang penderma (pesakit batuk kering). Semua  antibodi V gene yang mungkin 
diperkayakan dengan PCR konvensional kemudiannya diklonkan dalam  pLABEL, 
vektor fajmid. Pengklonan dua langkah telah digunakan untuk menjana perpustakaan 
antibodi. Anggaran saiz perpustakaan mini HC dan perpustakaan scFv yang dijana 
adalah 107 dan 109. Kadar penyelitan untuk teknik pengklonan dua langkah hanya 
mencapai 80% sahaja dan D-kristal antigen digunakan untuk verifikasi perpustakaan 
antibodi dan pemencilan monoklonal. Pemilihan monoklon antibodi dijalankan 
dengan mengunakan konvensional panning. Tiga monoklon scFv antibodi telah 
berjaya diperoleh untuk D-kristal antigen (Rv2331c) M.tuberculosis jujukan antibodi 
ini dianalisis menggunakan perisian IMGT. Klon tersebut adalah IGKV3 dan IGHV2 
untuk klon 1H, IGKV4 dan IGHV2 untuk klon 1B and IGLV1 dan LGHV1 untuk 
klon 10G. Antibodi diperkaya juga dinilai dalam bentuk larut untuk aktiviti 
mengikat. Kesimpulannya, perpustakaan scFv imun yang pelbagai ini telah 
dihasilkan dan mampu menjana antibodi monoklonal scFv yang larut air terhadap D-
kristal. 
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DEVELOPMENT OF AN IMMUNE TUBERCULOSIS ANTIBODY 
LIBRARY: MONOCLONAL ANTIBODY GENERATION FOR D-
CRYSTALLINE ANTIGEN 
 
ABSTRACT 
Antibodies are very important for therapeutic and diagnostic applications for 
infectious diseases. Immune libraries are useful for infectious disease applications 
because it would allow for better and selective enrichment of antibodies against 
disease antigens. The generations of antibody libraries are necessary to produce the 
monoclonal antibodies. Immune scFv antibody library was generated from six 
donors (tuberculosis patients). Conventional PCR method was used to amplify all 
possible antibody genes, which were then cloned into the pLABEL, phagemid 
vector. A two-step cloning procedure was done to generate the antibody library. The 
library size of the mini HC library and the scFv library constructed was 
approximately around 107 and 109 individual clones respectively. The insert rate for 
two-step cloning was only 63% and D-crystalline antigen was used for verification of 
the antibody library and monoclonal isolation. Conventional plate panning technique 
was used for selection of monoclonal antibodies. Three monoclonal scFv antibodies 
were successfully obtained for the Mycobacterium tuberculosis, D-crystalline 
(Rv2331c) antigen and the antibody sequence was analyzed using the software, 
VBASE2. The clones were IGKV3 and IGHV2 for clone 1H, IGKV4 and IGHV2 for 
clone 1B and IGLV1 and LGHV1 for clone 10G. The antibodies enriched was also 
evaluated in soluble form for binding activities. In conclusion, a diverse immune 
scFv library was constructed from which soluble monoclonal scFv antibodies against 
D-crystalline antigen was obtained.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Tuberculosis  
Tuberculosis (Tb) is important and highly infectious disease This disease is caused 
by the Mycobacterium tuberculosis (Mtb) bacterium and is considered a health threat 
to the world population. Tb is an airborne disease that can cause severe lung 
disability and high mortality. It is predominant in regions such as Southeast Asia and 
Africa (Demissie et al., 2006). It has become endemic because the human population 
density has increased from the 17th to 19th centuries (Acosta et al., 2011) with an 
estimated total of 480,000 people infected with multi drug resistant Tb (MDR Tb) 
(Prasad et al., 2014). Mtb is an acid-fast bacillus bacterium that grows very slow but 
can infect most mammals in the world (Collins, 1989). However, this disease only 
can be transmitted from human to human. Most infected individuals never realise 
they are infected because 90% of them never develop clinical symptoms in their 
lifetime and only about 2% of immunocompromised people become ill with primary 
tuberculosis (Garay, 1996).  
Bacille Calmette Guerin (BCG) is the only licensed vaccine against Tb  
(Goonetilleke et al., 2003). Most of the world's population is vaccinated with BCG 
during birth and later again during childhood because BCG can be effective in 
protecting young children against severe forms of Tb effectively, especially for 
meningeal (Fine, 1995). However, BCG is relatively not successful in preventing Tb 
infection in adults because BCG-immunized individuals can still be infected with 
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Mtb and develope active tuberculosis. The efficacy of BCG vaccine in human trials 
has varied from 0% to 80% (Flynn et al., 2004).  
The protection of BCG vaccine is debatable because a report on the efficacy to 
prevent adults from pulmonary Tb is contradictory (Jacob et al., 2009). BCG 
implementation becomes complicated because WHO has reported that there is no 
vaccine to children born from mother infected with positive HIV (Hesseling AC et 
al., 2009). However to prevent Tb, BCG remains as a standard vaccine in most 
countries across the world because it is the only cheap and efficient vaccine available 
in preventing the life threatening Tb from young children and infants. 
 
1.1.1 D-crystalline antigen 
The 16 kDa antigen of Mtb was previously referred to as the 14 kDa antigen (Jackett 
et al., 1988; Engers et al., 1986). It is also known as HSP16.3 that is correlated to 
low molecular weight heat-shock proteins (Beck et al., 2005). This Mtb is strictly 
aerobic but it can survive in microaerophilic environments as long as the changes is 
not too extreme (Wayne and Hayes, 1996). The D-crystalline antigen major protein 
located in the membrane layer of Mtb (Lee et al., 1992). 
This 16 kDa antigen plays a role in the survival of Mtb against macrophages 
activity(Kennaway et al., 2005). The physiology of this antigen is unique because it 
cannot be detected outside of Mtb bacillus Calmette-Guerin (BCG) (Yuan et al., 
1996; De Smet et al., 1996). The D-crystalline antigen has been targeted as one of the 
component antigens in vaccine strategies. This antigen is also targeted for protective 
immune responses against primary and reactivation of latent Tb infections (Taylor et 
al., 2012). This antigen contains a specific B-cell epitope in the Mtb complex 
(Demkow et al., 2002).  
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There is an association between Mtb cell wall thickening and 16 kDa antigen 
(Lee and Horwitz, 1999; Cunningham and Spreadbury, 1998). This antigen is not 
expressed during the exponential but rather during the latency phase (Yuan et al., 
1996). These properties make the 16 kDa antigen usefuk as a potential vaccine 
candidate to protect against of Mtb infection. 
 16 kDa antigen or HSP16.3 is an important agent for infection that will trigger 
cellular and humoral immune responses. Therefore, the study of this antigen in its 
role in pathogenicity and immunity of Tb is important (Siddiqui et al., 2014). The 
antigen specificity has made it a great candidate for detecting the disease at an early 
stage of infection (Rabahi et al., 2007; Verbon et al., 1992). This antigen is suitable 
for evaluation of a immune Tb library because it carries epitopes specific to Tb and 
is exposed to B-cell recognition (Coates et al., 1981). 
 
1.2 Immune system  
The human immune system is able to develop various defense mechanisms during 
infection to protect the body. The defense mechanisms act against virulence factors 
and destroy the invading pathogens in the body (Boyden, 1996). Antibodies have 
been proven over the years to be a desirable tool in both diagnostic and therapeutics 
management (Behring, 1890). There are two different types of protection for human, 
innate and adaptive immunities.  
The function of innate immunity is to fight off antigens when it appears in the 
body (Kindt et al., 2007). Two main functions of innate immunity are to determine 
the adaptive immune response and to kill the pathogen (Medzhitov and Janeway, 
1997; Fearon and Locksley, 1996). The physical barriers such as chemicals, skin and 
immune cells can attack foreign particles and ensure they never gain access into the 
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body. However, there are several strategies for pathogens to escape from being 
eliminated from the immune system. This includes the possibility of mimicking the 
host cell surface and continual variation of antigen surfaces.  
Second line of defense for human is adaptive immune response. The function is 
to block the infiltration of foreign pathogens. It is more complex than the innate 
immune response because it has the capability to differentiate self from non-self 
antigens and kill foreign microorganisms. It provides defense to eliminate and 
generate a memory towards it when the body is re-infected by the same foreign 
pathogen (Alberts et al., 2002).  
Adaptive immune system can be divided into two, cell-mediated immune 
system (T-lymphocytes) and humoral immune system (B-lymphocytes) 
(McCullough and Summerfield, 2005). B-lymphocytes in the humoral immune 
system are responsible for the production of antibodies. Plasma cell secreting 
antibodies are derived from B-lymphocytes. It can mature and develop into plasma 
cells when antigen bind to the B-cell receptor (Yancopoulos and Alt, 1986). 
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1.2.1 Antibody structure and class 
Antibodies are glycoproteins, also know as immunoglobulins (Ig). Antibodies are 
present in the tissue and serum of all vertebrates and mammals. It has a unique 
structure affinity to the target antigen (Padlan, 1994). B-cells are produced and 
mature in the bone marrow (Yancopoulos and Alt, 1896) and are responsible for 
humoral immune response to recognize the target antigen. Antibody is a heavy 
globular plasma protein with a size approximately 150 kDa.  
The basic Y shaped structure of all antibodies is similar (Figure 1.1). 
Antibodies have two types of polypeptide chains, heavy chains (HC) and light chains 
(LC) (Janeway et al., 2001). The HC fragment is larger and longer than LC with a 
size approximately 50 kDa or more. HC fragment can be further divided into four 
constant domains (CH1-CH4) (Normansell, 1987) while LC only have two different 
fragments with sizes around 22 kDa. However, the LC that is present in the antibody 
can only be in one form at a given time, either lambda or kappa fragment. LC 
fragments are linked to each other and to the HC fragment by disulphide bonds 
(Schroeder and Cavacini, 2010).   
Human antibodies can be divided into five different classes, namely IgG, IgA, 
IgD, IgE, and IgM (Davies and Metzger, 1983) classified based on their 
physiochemical, structural and immunological properties. IgM is predominant in the 
primary immune response (Cruse and Lewis, 2010) and structurally has an additional 
constant domain but does not contain the hinge region (Collins et al., 2002). IgA is 
predominant in mucus secretions and can exist as a monomer or dimer. IgE antibody 
plays a role against parasites and is normally found on basophils and mast cells of an 
individual (Cruse and Lewis, 2010).  
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IgD has a same basic structure as IgG but with an extended hinge region with 
an unknown function. However, IgG is the most widely used antibody isotype for 
therapeutics compared to other classes of antibodies (Carter, 2006). IgG is the main 
class antibodies to protect the body against bacterial and viral infections. It functions 
in humoral immune responses can be further divided to four different subclasses; 
IgG1, IgG2, IgG3, and IgG4. Each subclass of IgG antibody has different flexibility 
of the hinge region and number of disulfide bonds (Schroeder and Cavacini, 2010).  
The paratope is an antigen-binding site on antibodies while the epitope is a part 
of the antigen that is specifically recognized by antibodies (Hoogenboom and 
Chames, 2000). Both HC and LC antibody fragments are important for antigen 
binding and each one of them have different complementary determining regions 
(CDR).  
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Figure 1.1 Typical structure of antibody. (a) Antibody consists of two HC and two 
LC, which are linked together by disulphide bonds. One bond are linked together LC 
and HC, two bonds linked two HC and several bonds linking antibody subdomains. 
(b) Finger-like loops of a single LC whereby binding of antigen occur (Alberts et al., 
2013). 
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1.2.2 Antibody diversity  
Generally, before process maturation the diversity of antibodies is created at the 
germline level. During B cell development, the variable (V) and junction (J) 
segments for LC and V, D, and J segments for HC are joined together to form a 
functional of HC and LC repertoire by VDJ recombination (Marrack and Kappler, 
1987). VDJ segments rearrangement will create a unique HC and LC repertoire with 
large diversities. This creates the initial repertoire of antibody sequences that 
contributes to the primary diversity. 
Mutations of the rearranged variable region gene called somatic hypermutation 
(SHM) could also create antibody diversity (Di Noia and Neuberger, 2007). SHM 
allows for the secondary diversity to be generated resulting in higher affinity antigen 
binding sites (MacLennan, 1994). SHM mutations are mainly substitutions and alter 
the specificity of the encoded antibodies between ~150 to 200 bp downstream from 
promoter (Rada and Milstein, 2001).  
Random pairing of HC and LC repertoire also contributes to antibody 
diversity. The random combination of the associated HC and LC repertoire will 
increase the diversity of antibodies. Not only that, the diversity of antibodies also can 
be increase by changes of amino acid at CDR3 where the nucleotides can either be 
lost or added during VDJ rearrangement (Parslow et al., 2001). 
 
1.2.3 Recombinant antibodies 
Advances in molecular biology have led to the ability to produce antibodies in vitro 
without depending on hybridoma technology and animals. Recombinant antibodies 
can be used in all applications without triggering the intense immunogenic reactions 
in patients because the antibodies are derived from synthetic or natural human genes 
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(Weiner, 2006). The application of recombinant antibodies has increased over the 
last few years with the introduction of phage display technology (Frenzel et al., 
2013). It has highly specific diagnostic and therapeutic applications. This method 
also has an advantage in that it needs less purified antigen to produce antibodies 
(Baldi et al., 2007). Antibody genes are isolated and then incorporated into plasmid 
DNA vectors, which are then transferred into new expression hosts. Antibodies 
fragments are typically displayed on bacteriophage surfaces, a virus that infects 
bacteria by introducing the antibody DNA to the phage genome (McCafferty et al., 
1990).  
However, the Escherichia coli (E.coli) folding machinery has limitations. It 
only allows small fragments to be display (Dubel et al., 2010; Hoet et al., 2005). 
Therefore, only variable region genes are used instead of whole antibody molecules 
because antibodies fragments are more easily assembled in microorganism than 
whole antibody molecules. This makes presentation on phage surfaces suitable for 
smaller antibodies fragment. 
There are many antibody formats expressed as soluble proteins in prokaryotic 
and eukaryotic cells and these include disulfide-bond stabilized scFv (single chain 
fragment) (Schmiedl et al., 2000), single chain Fab fragments (scFab) combining 
scFv and Fab properties (Hust et al., 2007) as well as multi- and dimeric antibody 
formats (Hudson and Kortt, 1999; Hu et al., 1996) or minibodies (miniAbs) (Hu et 
al., 1996). Single domain antibody (sdAb) or nano body is the smallest antibody that 
contains of 11 only a single variable domain, either LC or HC fragment 
(Muyldermans, 2013) (Figure 1.2).  
 Fab and scFv are the most widely used antibody fragments for phage display. 
Fab is a larger format that consists of the constant and variable regions of the 
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antibody. The disulphide bond is formed between the LC fragments to the CH1 
domain of the HC fragment (Williams and Barclay, 1998). Fab format requires the 
expression, transportation, and assembly of both HC and LC in the periplasmic space 
(Foudeh et al., 2012). The scFv format only consists of variable regions HC and LC 
fragments with a short repetitive linker sequence (glycine and serine) to hold both 
fragments together. However, scFv molecule can form a dimer, trimer or tetramer 
depending on the length of the linker sequence (Hudson and Kortt, 1999).   
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Figure 1.2 Recombinant antibody formats for different applications compared to 
IgG. Red and dark red: Variable regions; Blue: Constant regions; Green: Peptide 
linkers; Yellow: Amphiphatic helices used for dimerization of scFv fragments 
(Frenzel et al., 2013). 
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1.2.4 Antibody libraries 
The collection of different antibody molecules cloned in phage vectors is called 
antibody phage library (Figure 1.3). Immune and naive libraries are constructed from 
natural human antibody gene diversity while synthetic and semi-synthetic libraries 
are constructed using chemically synthesized oligonucleotides based on designated 
gene sequences to exhibit similar diversities found in natural human antibody.  
A naïve or non-immune library is generated using the IgM repertoire from 
human B cells. It can be generated from spleen, bone marrow or from animal sources 
(Mark et al., 1991). Donors for this library must be healthy and have not been 
infected with any diseases at the time of collection. To generate a naïve repertoire, 
IgM antibody is a suitable immature repertoire that provides unbiased characteristics 
because it is produced at the early stage of development (Dobson et al., 2015). The 
large repertoires of this naïve library are generated from a pool collection of healthy 
donor and rearranged in vitro to increase the diversity (Marks, 2004). Advantages of 
this library are (i) a single library can be used for different types of antigens (ii) 
isolation of high affinity antibodies when large library repertoires are used. However, 
the construction of this library is very challenging and is time consuming because the 
size and diversity of the library required is larger compared to the immune library. 
The quality of the library generated is also influenced by the diverse expression of 
the V-gene repertoire due to the variation in immunity and genetic history of the 
donors.  
An immune library is normally derived from IgG mRNA of B-cells from 
animals or humans that have been exposed and infected by a certain type of disease 
(Azzazy and Highsmith, 2002; de Carvalho Nicacio et al., 2002). It is a typical 
library used in medical research because it is able to produce high quality and 
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affinity antibodies against the target antigen (Bazan et al., 2012). The size of an 
immune library can be smaller compared to other libraries because the repertoire 
consists of antibody with higher affinity against certain types of diseases. It is 
because of the polarization of the V-gene repertoire for antigen specificity in the B 
cells (Rahumatullah et al., 2015). Some of the antibodies have undergone affinity 
maturation through the immune system resulting in enrichment of antigen specific 
antibodies (Clackson et al., 1991; Skerra and Pluckthun, 1988). Some of the 
disadvantages of an immune library are (i) lack of immune response to self or toxic 
antigens, (ii) long time required for animal immunization, (iii) new antibody library 
must be constructed for different types of diseases and (iv) unpredictable immune 
responses to the target antigen (Cai and Garen, 1995).  
The synthetic library is constructed in vitro by chemically synthesized 
oligonucleotides that are assembled in vitro resulting in a fully synthetic construction 
of the antibody gene (Knappik et al., 2000). The repertoire can be made by 
randomizing sequences using PCR technique or direct mutagenesis in the CDR3 
region. There are several strategies to generate the synthetic repertoire including 
diversifying all three CDR loops in V-gene segment (Garrard and Henner, 1993) and 
randomizing the LC and HC repertoires (Akamatsu et al., 1993). This library is made 
up of a fixed framework and the diversity can be generated by synthetic 
oligonucleotides (Sidhu and Fellouse, 2006). Synthetic antibody repertoires can be 
easily generated using bioinformatics technology. Using this technology, stable and 
suitable structure of antibody can be identify (Ponomarenko et al., 2008). The 
advantage of such a library is that the repertoire has the potential to be controlled and 
the diversity can be clearly defined.  
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For a semi-synthetic library, the genetic information can be obtained from 
donors and randomized framework can be synthesized. This library is generated by 
fusion of the synthetic and naïve libraries (De Kruif et al., 1995). Naïve repertoire 
also can be presented in a semi-synthetic library. Therefore, these libraries can be 
used to produce antibody against any target antigens.  
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Figure 1.3 Different types of antibody libraries. (a) Generation of naïve libraries is 
from the B-cells isolation of non-immunized donor. (b) Generation of immunized 
libraries is from the B-cells isolation of immunized donor. (c) Generation of 
synthetic libraries are fully based on the computational design of the gene sequence 
(d) Generation of semi-synthetic libraries are combination of pre-designed segments 
and natural sources of gene sequence (Ponsel et al., 2011).  
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1.3 Phage display technology  
Phage display is one of the techniques used for antibodies identification by affinity 
isolation against target antigen. Smith and colleagues first introduced this method in 
1985 as a means to present foreign sequences on phage surfaces (Smith, 1985) and 
which has become an important tool for molecular evolution studies. This powerful 
technique allows for billions of different proteins or peptide, which are functionality 
intact (Paschke, 2006) to be displayed. It involves the expression of proteins, 
antibodies and peptides on the filamentous phage (Azzazy and Highsmith, 2002). 
Phage display allows the presentation of large peptide and protein libraries on 
the surface of filamentous phage, which leads to the selection of peptides and 
proteins, including antibodies, with high affinity and specificity to almost any target. 
The bacteriophage (or simply phage) mostly used in phage display technology, are 
single-stranded DNA viruses that infect a number of gram-negative bacteria. 
The presented antibodies can be used in a way similar to monoclonal 
antibodies that are important for cancer therapy and elucidating the specificity of 
autoimmune antibodies (Azzazy and Highsmith, 2002). It allows for rapid generation 
of monoclonal antibodies (Willats, 2002) that can be used for diagnostics and 
therapy. This technique is fast becoming a popular approach for in vitro selection and 
includes applications such as identification of interacting partners, evolution of 
enzymes and generation of antibodies (Li and Caberoy, 2010). 
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1.3.1 Structure of bacteriophages  
M13 helper phage is the most common filamentous phage used for phage display 
(Barbas and Barbas, 1994). In a phagemid system, the non-lytic M13 helper phage 
will co-infect E.coli cell containing F’ pilus, for example XL1 blue, ER 2738 and 
TG1 bacteria strains for phage packaging. Bacteriophage is a single stranded virus 
DNA that only infects gram-negative bacteria using the F’ pilus as a receptor 
(Russel, 1991). The size of a bacteriophage is around 6-10 nm diameter, 2000 nm in 
length and consists of 11 different genes (Zimmermann et al., 1986). The functions 
of these 11 genes can be divided into 4 types, i) coat protein (III, VI-IX), ii) phage 
assembly (I, IV and XI), iii) DNA replication (II and X) and iv) binding (ssDNA) 
(Figure 1.4). The bacteriophage mainly consists of 2700 copies of pVIII protein and 
3-5 copies each of the pVII and pIX proteins that form the phage head protein. PIII 
and pVI makes up the phage tail protein with each having 5 copies of protein for 
phage infection and stability (Russel et al., 1997). PIII and pVIII can be used for 
displaying peptide or protein in applications of phage display (Rodi and Makowski, 
1999).  
Life cycle of M13 phage can be divided into three stages, attachment, DNA 
replication and exportation. Infection starts when p3 of M13 phage attach to F pilus 
of E.coli. Single-stranded DNA of M13 enters the bacteria and convert into 
replicative form. Using replicative form as a template, DNA is replicative by rolling 
circle replication mechanism. Phage particles are assembled and extruded out 
bacterial membrane without cell lysis (Marvin, 1998). 
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Figure 1.4 Structure of filamentous phage particle. The coat proteins of the 
filamentous phage such as pIII, pVI, pVII, pVIII and pIX. During the phage 
assembly process, this end emerges first from the bacterium. The incorporation of the 
minor coat proteins pIII and pVI on the other end of the particle terminates the 
assembly process. pIII consists of three domains (N1, N2, and CT), which are 
connected by flexible linker regions. The binding of the N2 domain to the F pilus 
initiates the infection (Paschke, 2006). 
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1.3.2 Display formats  
The coat proteins that are commonly used for phage display are pVIII and pIII 
(Smith and Petrenko, 1997). They are normally involved in the cloning of 
recombinant phage antibodies and peptides (Dente et al., 1994). Foreign sequence 
either protein or peptide are inserted at the C-terminus of the pIII and pVIII on the 
vector. While, linker sequence of the HC and LC repertoire are normally inserted at 
the N-terminus. There are thousands of copies of pVIII coat protein that form the 
long cylindrical phage particle. However, there are only 3-5 functional domains for 
pIII coat protein (Webster. 1996). The pVIII coat protein only allows for short 
peptides or protein to be displayed on it because it could interrupt the interaction 
during assembly. On the other hand, pIII coat protein can tolerate large foreign 
molecules while maintaining the infectivity. Therefore, pIII coat protein is a suitable 
target protein for phage display. The recombinant antibodies are normally expressed 
as pIII fusion proteins. The antibodies will bind to the target antigen and the bound 
phage is detected with HRP labeled antibody (Dente et al., 1994).  
 
1.3.3 Antibody phage display  
Phage display has become a powerful application since 1985 that allows in vitro 
mimicking of the natural human antibody responses. This technique is a robust 
scientific research and diagnostic tool because it can isolate recombinant antibody 
repertoires with unique specificity (Winter et al., 1994; Griffiths, 1993). Antibody 
genes are fused to gene pIII of phage particle to generate an antibody phage library 
and create an association between antibody genotype and phenotype (Barbas et al., 
1991). The single antibody will be display by phage particle in accordance to the 
antibody genotype encoded by phage particle (Winter et al., 1994).  
 20 
ScFv (~35 kDa) and Fab (~60 kDa) antibody formats are favored in 
constructing phage antibody libraries due to difficulties displaying and assembling 
large antibody formats on the phage surface. Fab fragments are more stable than 
scFv because it consists of disulphide bonds and constant domains that hold the 
molecule together. Fab is normally chosen over the scFv format when a complete 
antibody format is needed as the final product (Feldhaus et al., 2003). The removal 
of the scFv linker might result in the changing of antigen binding. However, scFv 
with a smaller size has advantages compared to Fab because it has a better 
production yield as a fusion protein and easier to construct. However, to construct 
antibody libraries of either Fab or scFv it depends on the purpose of the antibodies 
for use in downstream applications (Carmen and Jermutus, 2002).  
 
1.3.4 Biopanning  
Biopanning is a process to identify unique phage clones that binds with the target 
antigen (Willats, 2002). This process is carried out to determine the antigen specific 
clones (Nissim et al., 1994; Clackson et al., 1991). The physical interaction between 
the phage particle and specific antibody allows for in vitro selection (Romanov, 
2003) (Figure 1.5). The phage library or phage clones is produced with standard 
molecular biology techniques involving the exploitation of DNA vectors to 
accommodate V-gene inserts and accommodate packaging to mature phage particles 
by making use of the E.coli machinery (Galanis et al., 1997).  
This biopanning technique is based on collection of repetitive cycles of 
amplification, incubation, washing and reselection of phage particles (Bazan et al., 
2012). After several rounds of affinity selections of the libraries, an enriched pool of 
antigen binding phage particles can be isolated. The target antigen can be 
 21 
immobilized onto microtiter plate wells, plastic tubes and columns with target-
activated matrix (Lomonosova et al., 2011) PVDF membrane (Liu et al., 2002), 
column matrix (Garet et al., 2010) and magnetic beads (Noronha et al., 2002). Target 
phage is captured during incubation and after that the washing step is carried out. 
This step was introduced to remove unbound phages and contaminants (Goodchild et 
al., 2005). Washing step is very important to wash off non-specifically bound phage 
from the microtiter plate. To obtain a strong binder of antibodies, more stringent 
washing conditions can be introduced. The antibody that is bound to the target 
antigen can be eluted either using base or acid solutions (Hoogenboom et al., 1998). 
For the next round of biopanning, the rescued phage clones are infected again with 
TG1 to be amplified as input phage. This continuous process will provide a 
concentrated pool of a selected population of antibodies after several rounds. 
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Figure 1.5 Biopanning process of phage display libraries. The antibodies are 
presented on the phage particle and add into immobilized target antigens for binders. 
The unbound phages are removed by several washing steps, elution and propagation 
of the bounded phages  (Singh et al., 2013).   
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1.4 Applications of phage display 
Phage display has provided a valuable alternative for the isolation of numerous 
peptides and proteins. It has been proven successful in generating antibodies against 
target antigens that are useful in a number of applications (Bratkovic, 2010). The 
advantages of phage display technology are mainly the speed to obtain monoclonal 
antibodies and an animal-free process. V-gene pool of synthetic libraries and healthy 
donors can be made artificially by generating diversity synthetically genes in the 
CDR.  
Phage display technology can also be used for direct isolation of antibodies 
against intracellular target molecules. Intrabodies are very good in modifying and 
visualizing the function of intracellular targets. Highly diverse scFv has been 
screened to select intrabodies due to the stability of scFv in reduced environments 
(Cardinale and Biocca, 2008). Phage display also has been widely used in anti-tumor 
activity. Antibody with tumor specificity can be used in cell toxic conjugates and 
target directed delivery of imaging agents (Zhou and Marks, 2009). Not only that, it 
also can reproduce antigenic epitopes by selecting anti-idiotypic antibodies (Zhikui 
et al., 2010). The potential application of phage derived human monoclonal 
antibodies for therapy and diagnostics is vast. 
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1.5 Problem statement and rationale of study  
Tuberculosis (Tb) is an infectious disease associated with high mortality and causes 
2-3 million deaths every year. The number of Tb infections has constantly increased 
over the past few years and the emergence of drug resistant strains for Tb (XDR, 
TDR) increases the urgency for alternative treatments. The concept of antibody-
based therapy for infectious diseases is increasing in recent years because it provides 
a potentially suitable alternative treatment especially for those infected with Mtb 
resistant strains (Saylor et al., 2009). However, a specific antibody therapy for Tb 
infection is not available. The challenge in antibody-based therapy is the discovery 
of effective monoclonal antibodies. Human antibodies have fewer side effects 
compared to conventional murine monoclonal antibodies. Therefore, phage display is 
the suitable method for generation of human monoclonal antibody.  
 In order to obtain good quality antibodies against a certain disease, the use of 
immune antibody libraries are preferred due to its skewed repertoire. This makes the 
generation of an immune Tb library very useful in terms of research and also lead to 
candidate isolation. As there is still no Tb immune antibody library reported to date, 
the generation of a Tb immune scFv antibody library is important to help with the 
growing concerns of Tb infection in the world. The focus on antibody-based 
immunity allows for a new perspective to be looked upon for Tb immunity. This is 
because traditional concepts of Tb immunity only involve the T-cell arm in the 
immune system with little focus given to the B-cell arm. However, this is no longer 
the case as several studies in recent years have highlighted the importance and role of 
B-cell immunology in Tb immunity (Cooper, 2009). This makes the role of an 
immune Tb library even more important in terms of the development of potential 
strategies for Tb therapy in the future. 
